HilleVax, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for HilleVax news (Ticker: HLVX), a resource for investors and traders seeking the latest updates and insights on HilleVax stock.

HilleVax, Inc. (HLVX) has been described in its public communications as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with an emphasis on virus-like particle (VLP) based vaccine candidates targeting norovirus-related acute gastroenteritis. The HLVX news feed on Stock Titan brings together company-issued press releases and SEC-referenced disclosures that trace both its clinical progress and its corporate transformation.

Readers can review announcements covering clinical trial milestones for HIL-214 and HIL-216, including topline data from the NEST-IN1 Phase 2b study in infants, the decision to discontinue further development of HIL-214 in infants, and statements about exploring potential continued development of norovirus vaccine candidates in adults. The news record also includes updates on financial results, such as quarterly and full-year reports that discuss research and development expenses, general and administrative costs, and the company’s cash, cash equivalents and marketable securities.

Another key theme in HilleVax’s news flow is strategic and corporate actions. In 2024, the company announced a workforce reduction intended to reduce operating expenses while maintaining core capabilities. In 2025, HilleVax disclosed that it was exploring strategic alternatives and later announced a definitive merger agreement under which XOMA Royalty Corporation would acquire all outstanding HilleVax shares for cash plus a contingent value right. Subsequent news and related SEC filings describe the tender offer, completion of the merger, and HilleVax’s transition to a wholly owned subsidiary of XOMA Royalty.

For investors and researchers, the HLVX news page serves as an archive of historical company developments, from clinical-stage vaccine work to the finalization of its acquisition and delisting from Nasdaq. Users interested in the evolution of HilleVax’s norovirus vaccine programs, its financial reporting history, and the structure of its merger with XOMA Royalty can use this page to follow the sequence of publicly reported events.